Unexplained cholestasis in adults and adolescents: diagnostic benefit of genetic examination

References

• European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;51:237–267.
   PubMed Web of Science ®Google Scholar
• Trauner M, Meier PJ, Boyer JL. Molecular pathogenesis of cholestasis. N Engl J Med. 1998;339:1217–1227.
   PubMed Web of Science ®Google Scholar
• Thompson R, Jansen PL. Genetic defects in hepatocanalicular transport. Semin Liver Dis. 2000;20:365–372.
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus C, Meier PJ. Pharmacogenetics of hepatocellular transporters. Pharmacogenetics. 2003;13:189–198.
   PubMedGoogle Scholar
• Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003;83:633–671.
   PubMed Web of Science ®Google Scholar
• Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 2003;23:315–322.
   PubMed Web of Science ®Google Scholar
• Fata CR, Gillis LA, Pacheco MC. Liver fibrosis associated with Crigler–Najjar syndrome in a compound heterozygote: a case report. Pediatr Dev Pathol. 2017;20:522–525.
   PubMed Web of Science ®Google Scholar
• Trotman BW, Shaw L, Roy-Chowdhury J, et al. Effect of phenobarbital on serum and biliary parameters in a patient with Crigler–Najjar syndrome, type II and acquired cholestasis. Digest Dis Sci. 1983;28:753–762.
   PubMed Web of Science ®Google Scholar
• Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J Rare Dis. 2007;2:27.
   PubMed Web of Science ®Google Scholar
• Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405–423.
   PubMed Web of Science ®Google Scholar
• Ziol M, Barbu V, Rosmorduc O, et al. ABCB4 heterozygous gene mutations associated with fibrosing cholestatic liver disease in adults. Gastroenterology. 2008;135:131–141.
   PubMed Web of Science ®Google Scholar
• Davit-Spraul A, Gonzales E, Baussan C, et al. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009;4:1172–1750.
   Web of Science ®Google Scholar
• Deleuze J, Jacquemin E, Dubuisson C, et al. Defect of multidrug‐resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology. 1996;23:904–908.
   PubMed Web of Science ®Google Scholar
• Jacquemin E, De Vree JM, Cresteil D, et al. The wide spectrum of multidrug resistance 3 deficiency: from neonatal cholestasis to cirrhosis of adulthood. Gastroenterology. 2001;120:1448–1458.
   PubMed Web of Science ®Google Scholar
• Gudbjartsson DF, Helgason H, Gudjonsson SA, et al. Large-scale whole-genome sequencing of the Icelandic population. Nat Genet. 2015;47:435–444.
   PubMed Web of Science ®Google Scholar
• Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics. 2007;17:47–60.
   PubMed Web of Science ®Google Scholar
• van Mil SW, van der Woerd WL, van der Brugge G, et al. Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology. 2004;127:379–384.
   PubMed Web of Science ®Google Scholar
• Strautnieks SS, Byrne JA, Pawlikowska L, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology. 2008;134:1203–1214. e8.
   PubMed Web of Science ®Google Scholar
• Lek M, Karczewski K, Minikel E, et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291
   Google Scholar
• Meier Y, Zodan T, Lang C, et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T > C polymorphism in the bile salt export pump. World J Gastroenterol. 2008;14:38–45.
   PubMed Web of Science ®Google Scholar
• Allen RM, Marquart TJ, Albert CJ, et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med. 2012;4:882–895.
   PubMed Web of Science ®Google Scholar
• Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)‐B* 57: 01‐restricted activation of drug‐specific T cells provides the immunological basis for flucloxacillin‐induced liver injury. Hepatology. 2013;57:727–739.
   PubMed Web of Science ®Google Scholar
• Dixon PH, Wadsworth CA, Chambers J, et al. A comprehensive analysis of common genetic variation around six candidate loci for intrahepatic cholestasis of pregnancy. Am J Gastroenterol. 2014;109:76–84.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Castaño G, Burgueño A, et al. Association of the multidrug-resistance-associated protein gene (ABCC2) variants with intrahepatic cholestasis of pregnancy. J Hepatol. 2008;48:125–132.
   PubMed Web of Science ®Google Scholar
• Dixon PH, Sambrotta M, Chambers J, et al. An expanded role for heterozygous mutations of ABCB4, ABCB11, ATP8B1, ABCC2 and TJP2 in intrahepatic cholestasis of pregnancy. Sci Rep. 2017;7:11823.
   Web of Science ®Google Scholar
• Togawa T, Sugiura T, Ito K, et al. Molecular genetic dissection and neonatal/infantile intrahepatic cholestasis using targeted next-generation sequencing. J Pediatr. 2016;171:171–177. e4.
   PubMed Web of Science ®Google Scholar
• El-Sheikh AA, van den Heuvel JJ, Koenderink JB, et al. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J Pharmacol Exp Ther. 2007;320:229–235.
   PubMed Web of Science ®Google Scholar
• Vlaming ML, Pala Z, van Esch A, et al. Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate. Clin Cancer Res. 2008;14:8152–8160.
   PubMed Web of Science ®Google Scholar
• Vogel I, Ott P, Lildballe D, et al. Isolated congenital hepatic fibrosis associated with TMEM67 mutations: report of a new genotype–phenotype relationship. Clin Case Rep. 2017;5:1098–1102.
   Web of Science ®Google Scholar
• Buch S, Schafmayer C, Völzke H, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Genet. 2007;39:995–999.
   PubMed Web of Science ®Google Scholar
• von Kampen O, Buch S, Nothnagel M, et al. Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at the ABCG5/8 lithogenic locus. Hepatology. 2013;57:2407–2417.
   PubMed Web of Science ®Google Scholar
• Kadakol A, Sappal BS, Ghosh SS, et al. Interaction of coding region mutations and the Gilbert-type promoter abnormality of the UGT1A1 gene causes moderate degrees of unconjugated hyperbilirubinaemia and may lead to neonatal kernicterus. J Med Genet. 2001;38:244–249.
   PubMed Web of Science ®Google Scholar
• Fisk N, Bruce Storey G. Fetal outcome in obstetric cholestasis. BJOG. 1988;95:1137–1143.
   Google Scholar
• Dröge C, Bonus M, Baumann U, et al. Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants. J Hepatol. 2017;67:1253–1264.
   PubMed Web of Science ®Google Scholar
• Thompson RJ. Sequencing of transporter genes in cholestasis: we are still learning. J Hepatol. 2017;67:1132–1133.
   PubMed Web of Science ®Google Scholar
• Sambrotta M, Strautnieks S, Papouli E, et al. Mutations in TJP2 cause progressive cholestatic liver disease. Nat Genet. 2014;46:326–328.
   PubMed Web of Science ®Google Scholar
• Graf GA, Yu L, Li WP, et al. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J Biol Chem. 2003;278:48275–48282.
   PubMed Web of Science ®Google Scholar
• Gonzales E, Taylor SA, Davit-Spraul A, et al. MYO5B mutations cause cholestasis with normal serum gamma-glutamyl transferase activity in children without microvillous inclusion disease. Hepatology. 2017;65:164–173.
   PubMed Web of Science ®Google Scholar
• Gomez-Ospina N, Potter CJ, Xiao R, et al. Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis. Nat Commun. 2016;7:10713.
   PubMed Web of Science ®Google Scholar
• van de Steeg E, Stranecky V, Hartmannova H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest. 2012;122:519–528.
   PubMed Web of Science ®Google Scholar
• Elens L, Tyteca D, Panin N, et al. Functional defect caused by the 4544G > A SNP in ABCC2: potential impact for drug cellular disposition. Pharmacogenet Genomics. 2011;21:884–893.
   PubMed Web of Science ®Google Scholar
• Floreani A, Carderi I, Variola A, et al. A novel multidrug‐resistance protein 2 gene mutation identifies a subgroup of patients with primary biliary cirrhosis and pruritus. Hepatology. 2006;43:1152–1154.
   PubMed Web of Science ®Google Scholar
• Arlanov R, Porter A, Strand D, et al. Functional characterization of protein variants of the human multidrug transporter ABCC2 by a novel targeted expression system in fibrosarcoma cells. Hum Mutat. 2012;33:750–762.
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. 1995;333:1171–1175.
   PubMed Web of Science ®Google Scholar